User login
Helmholtz-Zentrum Geesthacht (HZG)
Location
Kantstraße 55
14513
Teltow
Email address:
teltow@hzg.de
Phone:
(03328) 35 24 50
Fax:
(03328) 35 24 52
Website:
www.hzg.de
Institute of Biomaterial Science
Fundamental research at the Institute of Biomaterial Science (former Centre for Biomaterial Development) in Teltow is focused on the development of multifunctional, polymer-based materials for applications in Regenerative Medicine. Multifunctional biomaterial systems allow tailoring of material properties and functions (e.g. shape- memory effect or the capability of controlled drug release) to the requirements of a specific application.
These complex demands cannot be completely fulfilled by the materials established in clinics. The research strategy follows a comprehensive approach by addressing design, synthesis, and processing of biomaterials, testing for cell tolerance, immune response and toxicity, as well as examination of interactions of polymers with biological environments.
The research and innovation platform “biomaterial science and bioactive environments”, which could be realized in Teltow with the establishment of the Biomedical Technology Centre, allows the production of cell culture devices, implants and controlled drug delivery systems both on a laboratory scale and on scales suitable for pre-clinical or clinical tests.
The translation of the results from fundamental research in clinical applications is performed especially at the Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), which is the jointly operated clinical translation centre of Charité, Universitätsmedizin Berlin and Helmholtz-Zentrum Geesthacht, Teltow.
These complex demands cannot be completely fulfilled by the materials established in clinics. The research strategy follows a comprehensive approach by addressing design, synthesis, and processing of biomaterials, testing for cell tolerance, immune response and toxicity, as well as examination of interactions of polymers with biological environments.
The research and innovation platform “biomaterial science and bioactive environments”, which could be realized in Teltow with the establishment of the Biomedical Technology Centre, allows the production of cell culture devices, implants and controlled drug delivery systems both on a laboratory scale and on scales suitable for pre-clinical or clinical tests.
The translation of the results from fundamental research in clinical applications is performed especially at the Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), which is the jointly operated clinical translation centre of Charité, Universitätsmedizin Berlin and Helmholtz-Zentrum Geesthacht, Teltow.
